Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
The French group takes a shot at Perspective with its second bet on Orano Med.
For $850m up front Roche gets to challenge Pfizer.
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
What similarly acting projects are still unpartnered?
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.